‘Moderna Inc has begun dosing patients in a mid-to-late stage study of its COVID-19 vaccine, mRNA-1273, in children aged six months to less than 12 years, the company said on Tuesday (Mar 16). The study will assess the safety and effectiveness of two doses of mRNA-1273 given 28 days apart and intends to enrol about 6,750 children in the United States and Canada.’
Read here (Channel News Asia, Mar 16, 2021)
